A synthesised short peptide from Vladimir Khavinson’s bioregulator programme, directed at cardiac tissue and studied for effects on cell survival and contractile function in the heart.

Why is there a bioregulator specifically for the heart?

Because heart muscle has very limited capacity to replace its own cells. Most tissue turns over — skin in weeks, gut lining in days — but the cardiomyocytes you have are largely the ones you keep, which makes maintenance rather than replacement the research focus.

How strong is the evidence?

Weak. The published record is small, preclinical, and comes largely from the institute that developed the compound. Cardiovascular research usually demands large outcome trials, so the gap between this literature and normal standards in that field is particularly noticeable.

What happens when heart muscle is damaged?

The lost tissue is replaced with scar rather than rebuilt. Scar holds the structure together but does not contract, so the organ remains structurally intact while becoming functionally smaller. This is why maintenance rather than repair is the framing for cardiac research.

Research Library›Bioregulators & Neuropeptides›Cardiogen

Cardiac Bioregulator

Cardiogen: The Peptide for the Muscle That Never Rests

Q: Why does heart muscle not regenerate?

Adult cardiac muscle cells divide extremely rarely — estimates suggest only a small percentage are renewed across an entire adult lifetime. Unlike skin, gut lining or blood, the heart largely keeps the cells it finished growing with.

A four-amino-acid sequence aimed at cardiac tissue — an organ with almost no capacity to replace its own cells, which is precisely why maintenance research focuses on it.

5 min read·4 studies cited·Updated July 2026

Evidence level

Preclinical only — animal and cell studies

What this level means

Quick Reference

Sequence	Ala-Glu-Asp-Arg (AEDR)
Target tissue	Heart
Generation	Synthetic (second-generation)
Family	Khavinson bioregulators

What Is Cardiogen?

Cardiogen is a synthesised tetrapeptide from the Khavinson family, directed at heart tissue. The name follows the family convention — Cardio-gen, from cardiac.

Why the heart is a special case, in plain language: most tissue in your body replaces itself. Skin turns over in weeks, the gut lining in days, the liver can regrow after damage. Heart muscle largely cannot. The cardiomyocytes you finish childhood with are broadly the ones you keep, beating around a hundred thousand times a day for eighty years without a night off. When a factory cannot replace its machines, maintenance stops being routine and becomes the entire strategy. That is the reasoning behind studying a maintenance signal specifically for cardiac tissue.

What the Research Examines

Published work examines Cardiogen in models of cardiac stress and ageing, looking at markers of cell survival, contractile function and apoptosis — programmed cell death — in cardiac tissue.

The evidence base is small and preclinical, drawn overwhelmingly from the originating institute. This is worth weighing carefully: cardiovascular research is a field with unusually demanding evidence standards, where large outcome trials are the norm, so the distance between this literature and its surrounding field is especially wide. There is no regulatory approval anywhere.

The Organ That Cannot Replace Its Workers

Most tissue replaces itself. Skin turns over in weeks, gut lining in days, blood cells continuously. Heart muscle very largely does not.

Adult cardiac muscle cells divide extremely rarely. Estimates suggest only a small percentage are renewed across an entire adult lifetime. For practical purposes, the heart cells you finish growing with are the ones you keep.

Picture a business where nobody can be replaced. Ordinary organs are staffed by people who retire and are succeeded — the work continues because the roles refill. The heart is staffed by people who must last the whole life of the company. When one is lost, the job does not get reassigned; the remaining staff simply carry more.

This is why damage to heart muscle is so consequential. Lost tissue is not rebuilt — it is replaced with scar, which holds the structure together and does not contract. The organ becomes structurally intact and functionally smaller.

It also explains why maintenance is the framing for cardiac research in a way it is not for tissues that renew. Where replacement is not available, keeping existing cells functioning is the only lever there is.

Frequently Asked Questions

Compiled by the Southern Pacific Labs research team. Last updated July 2026.

Browse the research range →

Published References

Khavinson VK, Malinin VV. “Gerontological Aspects of Genome Peptide Regulation.” Karger AG, Basel, 2005. Source
Anisimov VN, Khavinson VKh. “Peptide bioregulation of aging: results and prospects.” Biogerontology, 2010. PubMed
Khavinson VKh. “Peptides and Ageing.” Neuro endocrinology letters, 2002. PubMed
Fedoreyeva LI, Kireev II, Khavinson VKh, et al. “Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.” Biochemistry. Biokhimiia, 2011. PubMed